Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Oxford spinouts score $61m in first quarter
The total raised by Oxford’s spinouts was down from $229m year-on-year, though university tech transfer office OUI also marked its largest ever single exit during the period.
Gyroscope enters Orbit for merger
Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.
Willow Biosciences follows public path
Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.
Analysis: Slow and steady does it in the first quarter
The first quarter of 2019 may not have broken records, but it puts the year on track for a solid performance after the historic successes of the previous 12 months.
Oxford Nanopore sets sights on IPO
The Oxford University genetic sequencing spinout is reportedly mulling an IPO that would provide exits to investors including commercialisation firm IP Group.
Precision Bio hits public markets with $126m
The corporate-backed genome editing technology developer Precision BioSciences, which was spun out of Duke University, floated in the middle of its range and is now valued at more than $780m.
Liftupp climbs with ExamSoft
Liverpool's health sciences academic assessment software spinout has been bought by exam platform ExamSoft, which will augment and integrate its services.
EMV Capital rescues Vortex and Wanda
NetScientific has exited its loss-making portfolio companies Vortex and Wanda after originally deciding to close the two medical diagnostics ventures last week.

Other News

Graphine combines with Unity
Ghent University-founded texture streaming technology creator Graphine has been picked up by Unity Technologies, providing an exit to research institute Imec’s iStart accelerator.
Wanda and Vortex to vacate stage
Embattled commercialisation firm NetScientific is closing two medical diagnostics spinouts from UCLA after both failed to attract external funding.
NervGen Pharma holds nerve for $7.5m IPO
CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.
Parkwalk shifts return in Animal Dynamics
Parkwalk Advisors has sold on most of its stake in Oxford-founded drone designer Animal Dynamics, securing a 6.9 times return.
Precision Bio pinpoints $100m IPO target
Genomic medicine developer Precision Biosciences plans to raise up to $100m in an upcoming IPO that could hand exits to Duke University and corporates Amgen, EMS and Baxter.
Big deal: Nightstar shines bright in $800m acquisition
Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg